wherein: B is a non-internalizing binding moiety specific for a cancer associated protein D is a cytotoxic drug moiety and L is a linker group that undergoes cleavage in vivo for releasing said drug moiety in an active form. The binding moiety is a ligand for the cancer associated protein whereby drawbacks associated with the use of internalizing ligands are avoided.
